Source
Sahi
Zydus Lifesciences is advancing its clinical pipeline with permission to start Phase III clinical trials of Desidustat, an oral therapeutic candidate for Sickle Cell Disease. The 203-day trial will enroll 164 patients in collaboration with the Indian Council of Medical Research (ICMR). Desidustat already holds US FDA Orphan Drug Designation and represents a promising oral alternative to painful management protocols and expensive blood transfusions.
News Url